Marr Bio is a pioneering company in the field of in vitro diagnostic reagents, specializing in non-invasive HIV test products. The company operates in both domestic and international markets, serving organizations and institutions such as the United States GAP affiliated to the US CDC China Office, China Gates HIV Program, and the National CDC National Center. Marr Bio's core product, Aware, is a non-invasive HIV test that has been certified by the China Food and Drug Administration (CFDA) since 2008. The company prides itself on its commitment to quality and precision, sourcing core raw materials from the world's best suppliers and maintaining ISO 9001 and ISO 13485 certifications for its production facilities. With an annual production capacity of 100 million units, Marr Bio covers the entire industrial chain from research and development to production and sales. The company's business model is distinct from the traditional reagent industry, driven by the positioning of POCT (Point-of-Care Testing) FMCG (Fast-Moving Consumer Goods) Internet products. This innovative approach has resulted in a nearly 100% annual growth rate and a market share of nearly 60% for its flagship product, Aware. Marr Bio generates revenue through the sale of its diagnostic products to healthcare providers, research institutions, and public health organizations. The company holds several patents, including Chinese invention patents, utility models, and design patents for its saliva-based HIV detection technology.

Keywords: non-invasive HIV test, in vitro diagnostics, POCT, FMCG, ISO certifications, CFDA certified, patents, saliva detection, healthcare, rapid growth.